|
07 Jun 2019 |
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)
|
|
07 Jun 2019 |
Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
|
|
07 Jun 2019 |
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
|
|
07 Jun 2019 |
Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-887 for Kidney Disease
|
|
07 Jun 2019 |
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
|
|
07 Jun 2019 |
Vivacelle Bio Announces Submission of an IND Application with U.S. FDA for VBI-S, an Injectable Fluid for the Treatment of Patients with Severe Septic Shock
|
|
07 Jun 2019 |
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics
|
|
06 Jun 2019 |
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia
|
|
06 Jun 2019 |
AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
|
|
06 Jun 2019 |
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
|
|
06 Jun 2019 |
Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
|
|
06 Jun 2019 |
Innate pharma enrolls first patient in IPH4102 TELLOMAK phase II study
|
|
06 Jun 2019 |
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
|
|
06 Jun 2019 |
Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones
|
|
06 Jun 2019 |
Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations
|
|
06 Jun 2019 |
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
|
|
06 Jun 2019 |
Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
|
|
06 Jun 2019 |
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
|
|
05 Jun 2019 |
FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
|
|
04 Jun 2019 |
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib
|
